What is a recommended taper schedule for a patient starting at 2mg of Suboxone (buprenorphine/naloxone) per day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Suboxone (Buprenorphine/Naloxone) Tapering Schedule for Patients on 2mg Daily

For patients starting at 2mg of Suboxone daily, a decrease of 10% of the previous dose every 2-4 weeks is recommended as the optimal tapering schedule to minimize withdrawal symptoms and maximize successful discontinuation. 1

General Tapering Principles

  • A slow taper is essential to minimize withdrawal symptoms which can include drug craving, anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, mydriasis, tremor, and tachycardia 1
  • Tapers may need to be paused and restarted when the patient is ready, especially when reaching lower doses 1
  • Success should be measured by patient progress rather than rigid adherence to a schedule 1
  • Withdrawal symptoms should be actively monitored and managed throughout the tapering process 1

Recommended Tapering Schedule for 2mg Starting Dose

  • Week 1-4: Maintain at 2mg daily to ensure stability 1
  • Week 5-8: Reduce to 1.8mg daily (10% reduction) 1
  • Week 9-12: Reduce to 1.6mg daily (10% reduction) 1
  • Week 13-16: Reduce to 1.4mg daily (10% reduction) 1
  • Week 17-20: Reduce to 1.2mg daily (10% reduction) 1
  • Week 21-24: Reduce to 1.0mg daily (10% reduction) 1
  • Week 25-28: Reduce to 0.8mg daily (10% reduction) 1
  • Week 29-32: Reduce to 0.6mg daily (10% reduction) 1
  • Week 33-36: Reduce to 0.5mg daily (10% reduction) 1
  • Week 37-40: Reduce to 0.4mg daily (10% reduction) 1
  • Week 41-44: Reduce to 0.3mg daily (10% reduction) 1
  • Week 45-48: Reduce to 0.2mg daily (10% reduction) 1
  • Week 49-52: Reduce to 0.1mg daily (10% reduction) 1
  • Week 53-56: Extend dosing interval to every other day at 0.1mg 1
  • Week 57-60: Extend to every third day at 0.1mg, then discontinue 1

Adjusting the Taper

  • If withdrawal symptoms become severe, return to the previous well-tolerated dose and slow the taper further 1
  • For patients who have been on Suboxone for years, consider an even slower taper of 10% per month 1
  • More rapid tapers might be needed in cases of severe adverse events, but these carry higher risk of withdrawal and relapse 1

Managing Withdrawal Symptoms

  • Protracted withdrawal symptoms may include dysphoria, irritability, insomnia, and anhedonia even months after discontinuation 1
  • Adjunctive medications may be used to manage specific withdrawal symptoms:
    • For anxiety/agitation: Clonidine 0.1-0.2mg every 6 hours as needed 1
    • For insomnia: Short-term trazodone 50-100mg at bedtime 1
    • For muscle aches: Acetaminophen or NSAIDs 1
    • For GI symptoms: Loperamide for diarrhea, ondansetron for nausea 1

Important Considerations and Pitfalls

  • Studies show that most patients attempting to taper off opioid agonist therapy are not successful, so set realistic expectations 2
  • Research indicates that shorter tapers (e.g., 7 days) may actually show better short-term outcomes than longer tapers (28 days), but long-term success rates are similar and generally low 3
  • Avoid setting arbitrary time limits for completing the taper; individualize based on patient response 1
  • Never abruptly discontinue Suboxone due to risk of withdrawal 1
  • Provide close monitoring and support throughout the tapering process 1
  • Consider offering naloxone for overdose prevention, especially for patients with history of overdose or substance use disorder 1

Follow-up Schedule

  • Evaluate patients within 1-4 weeks of starting the taper and after each dose reduction 1
  • More frequent follow-up (every 1-2 weeks) is recommended during the initial phase of tapering 1
  • Continue regular monitoring throughout the entire tapering process and for several months after discontinuation to assess for protracted withdrawal and relapse 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Buprenorphine tapering schedule and illicit opioid use.

Addiction (Abingdon, England), 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.